Evotec logo

Evotec Stock

StockStock
ISIN: DE0005664809
Ticker: EVT
DE0005664809
EVT

Price

Frequently asked questions

What is Evotec's market capitalization?

The market capitalization of Evotec is $1.40B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Evotec?

Evotec's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.049. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Evotec's stock?

Currently, 10 analysts cover Evotec's stock, with a consensus target price of $23.48. Analyst ratings provide insights into the stock's expected performance.

What is Evotec's revenue over the trailing twelve months?

Over the trailing twelve months, Evotec reported a revenue of $858.38M.

What is the EBITDA for Evotec?

Evotec's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$79.58M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Evotec?

Evotec has a free cash flow of -$267.48M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Evotec's stock?

The 5-year beta for Evotec is 0.96. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Evotec have, and what sector and industry does it belong to?

Evotec employs approximately 5,022 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Evotec's shares?

The free float of Evotec is 175.52M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$1.40B

5Y beta

 
0.96

EPS (TTM)

 
-$1.049

Free Float

 
175.52M

Revenue (TTM)

 
$858.38M

EBITDA (TTM)

 
-$79.58M

Free Cashflow (TTM)

 
-$267.48M

Pricing

1D span
$7.596$7.854
52W span
$5.541$24.09

Analyst Ratings

The price target is $23.48 and the stock is covered by 10 analysts.

Buy

8

Hold

2

Sell

0

Information

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

5,022

Biotechnology & Drugs

Health Care

Identifier

ISIN

DE0005664809

Primary Ticker

EVT

Knockouts

Join the conversation